Given the critical role of CGRP in regulating neuroinflammation post-cerebral infarction and its potential for clinical translation, we developed a biomimetic membrane-based nanoparticle delivery system (CGRP-NM@NPs), which leverages the CXCR4-mediated bone marrow homing capability of senescent neutrophils to achieve targeted bone marrow delivery of CGRP 37, thereby avoiding its hypotensive side effects and enhancing its half-life and local concentration. The gene discussed is CXCR4; the disease is cerebral infarction.